Ampliphi Biosciences Stock Price, News & Analysis (NYSEAMERICAN:APHB) $2.50 -0.10 (-3.85%) (As of 12/6/2023 ET) Add Compare Share Share Today's Range$2.50▼$2.6050-Day Range N/A52-Week Range$0.15▼$1.37Volume29,156 shsAverage Volume842,200 shsMarket Capitalization$83.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsStock AnalysisChartFinancialsHeadlinesSEC Filings About Ampliphi Biosciences Stock (NYSEAMERICAN:APHB)AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.Read More APHB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APHB Stock News HeadlinesOctober 24, 2023 | benzinga.comPacific Biosciences Stock (NASDAQ:PACB), Analyst Ratings, Price Targets, PredictionsJanuary 25, 2023 | finance.yahoo.comAkston Biosciences Strengthens Board with Addition of John T. PrestonDecember 7, 2023 | Financial Alphas (Ad)Recent Reports Are A Wake-Up Call For InvestorsAs the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.January 5, 2023 | benzinga.comSelecta Biosciences Stock (NASDAQ:SELB), Quotes and News SummaryOctober 27, 2021 | finance.yahoo.comAPHB: Case Study on AB-PA01 Presented at ISHLT Annual MeetingApril 30, 2020 | www.bloomberg.comLifshitz & Miller LLP Announces Investigation of AmpliPhi Biosciences Corporation, Churchill Capital Corporation, DaVita Inc.,May 9, 2019 | finance.yahoo.comC3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc.May 8, 2019 | finance.yahoo.comAmpliPhi Biosciences Announces Stockholder Approval of Business Combination with C3J TherapeuticsDecember 7, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comApril 2, 2019 | www.businesswire.comC3J Therapeutics Announces Issuance of U.S. Patent Covering Synthetic BacteriophageMarch 27, 2019 | finance.yahoo.comSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AmpliPhi Biosciences Corporation - APHBMarch 25, 2019 | finance.yahoo.comAmpliPhi Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business HighlightsMarch 18, 2019 | www.nasdaq.comAmpliPhi Biosciences Corporation Estimate MomentumJanuary 15, 2019 | seekingalpha.comAmpliPhi Biosciences Corp. (APHB) CEO Paul Grint on C3J Therapeutics Merger Conference Call (Transcript)January 4, 2019 | www.bizjournals.comAmpliPhi Biosciences and C3J Therapeutics Agree to MergeJanuary 4, 2019 | seekingalpha.comAmpliPhi Bio up 45% premarket on merger with C3J TherapeuticsDecember 18, 2018 | seekingalpha.comAmpliPhi Biosciences optimizes manufacturing process and scale up for AB-SA01December 18, 2018 | finance.yahoo.comAmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical DevelopmentSee More Headlines Receive APHB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ampliphi Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2019Today12/07/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:APHB Previous SymbolAMEX:APHB CUSIPN/A CIK921114 Webwww.ampliphibio.com Phone+1-804-8272524FaxN/AEmployees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares33,469,000Free FloatN/AMarket Cap$83.67 million OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Paul C. Grint (Age 61)CEO & Director Mr. Steven R. Martin (Age 58)Sr. VP & CFO Mr. Michael Scott Salka (Age 57)Consultant Key CompetitorsVeruNASDAQ:VERUNervGen PharmaOTCMKTS:NGENFCompugenNASDAQ:CGENChromaDexNASDAQ:CDXCCurisNASDAQ:CRISView All Competitors APHB Stock Analysis - Frequently Asked Questions How were Ampliphi Biosciences' earnings last quarter? Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) posted its quarterly earnings data on Monday, March, 25th. The biotechnology company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.07. What other stocks do shareholders of Ampliphi Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ampliphi Biosciences investors own include Navios Maritime Partners (NMM), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Synergy Pharmaceuticals (SGYP), AcelRx Pharmaceuticals (ACRX), Athersys (ATHX), Actinium Pharmaceuticals (ATNM), Anavex Life Sciences (AVXL) and Corbus Pharmaceuticals (CRBP). How do I buy shares of Ampliphi Biosciences? Shares of APHB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSEAMERICAN:APHB) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ampliphi Biosciences Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.